Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Combivir
2. Lamivudine, Zidovudine Drug Combination
1. Lamivudine + Zidovudine
2. 165456-81-5
3. 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;1-[(2r,4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
4. Lamivudine; Zidovudine
5. Zidovudine / Lamivudine
6. Lamivudine / Zidovudine
7. Lamivudine, Zidovudine Drug Combination
8. 3tc / Zdv
9. Combivir(tm)
10. Lamivudine Mixture With Zidovudine
11. Zidovudine Mixture With Lamivudine
12. Epivir & Retrovir
13. 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; 1-[(2r,4s,5s)-4-azido-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione
14. Mixture Of Lamivudine And Zidovudine
15. Lamivudine & Zidovudine
16. 3tc & Zdv
17. Azt & 3tc & Sst
18. (-)-3tc & Azt
19. .beta.-l-(-)-2',3'-dideoxy-3'-thiacytidine & 3'-azido-3'-deoxythymidine
20. .beta.-l-(-)-2',3'-dideoxy-3'-thiacytidine & 3'-azido-3'-deoxythymidine & Sho-saiko-to
21. Thymidine, 3'-azido-3'-deoxy-, Mixt. With 4-amino-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1h)-pyrimidinone
| Molecular Weight | 496.5 g/mol |
|---|---|
| Molecular Formula | C18H24N8O7S |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 5 |
| Exact Mass | 496.14886631 g/mol |
| Monoisotopic Mass | 496.14886631 g/mol |
| Topological Polar Surface Area | 207 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 815 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Lamivudine and zidovudine |
| Drug Label | COMBIVIR: COMBIVIR Tablets are combination tablets containing lamivudine and zidovudine. Lamivudine (EPIVIR) and zidovudine (RETROVIR, azidothymidine, AZT, or ZDV) are synthetic nucleoside analogues with activity against HIV-1.COMBIVIR Tablets are fo... |
| Active Ingredient | Lamivudine and zidovudine; Lamivudine; zidovudine |
| Dosage Form | Tablet |
| Route | oral; Oral |
| Strength | 150mg; 300mg |
| Market Status | Tentative Approval; Prescription |
| Company | Mylan Pharms; Hetero Labs Ltd V; Aurobindo Pharma; Lupin; Teva Pharms; Strides Arcolab |
| 2 of 4 | |
|---|---|
| Drug Name | Lamivudine; zidovudine |
| Active Ingredient | efavirenz; Lamivudine; zidovudine |
| Dosage Form | Tablet, for suspension; Tablet |
| Route | oral; oral suspension |
| Strength | 60mg; 30mg; 150mg; 600mg; 300mg |
| Market Status | Tentative Approval |
| Company | Macleods Pharma; Hetero Drugs; Aurobindo; Mylan Labs; Aurobindo Pharma; Cipla; Pharmacare; Matrix Labs; Emcure Pharma |
| 3 of 4 | |
|---|---|
| Drug Name | Lamivudine and zidovudine |
| Drug Label | COMBIVIR: COMBIVIR Tablets are combination tablets containing lamivudine and zidovudine. Lamivudine (EPIVIR) and zidovudine (RETROVIR, azidothymidine, AZT, or ZDV) are synthetic nucleoside analogues with activity against HIV-1.COMBIVIR Tablets are fo... |
| Active Ingredient | Lamivudine and zidovudine; Lamivudine; zidovudine |
| Dosage Form | Tablet |
| Route | oral; Oral |
| Strength | 150mg; 300mg |
| Market Status | Tentative Approval; Prescription |
| Company | Mylan Pharms; Hetero Labs Ltd V; Aurobindo Pharma; Lupin; Teva Pharms; Strides Arcolab |
| 4 of 4 | |
|---|---|
| Drug Name | Lamivudine; zidovudine |
| Active Ingredient | efavirenz; Lamivudine; zidovudine |
| Dosage Form | Tablet, for suspension; Tablet |
| Route | oral; oral suspension |
| Strength | 60mg; 30mg; 150mg; 600mg; 300mg |
| Market Status | Tentative Approval |
| Company | Macleods Pharma; Hetero Drugs; Aurobindo; Mylan Labs; Aurobindo Pharma; Cipla; Pharmacare; Matrix Labs; Emcure Pharma |
Anti-HIV Agents
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)
Reverse Transcriptase Inhibitors
Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
A Lamivudine, Zidovudine Drug Combination manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lamivudine, Zidovudine Drug Combination, including repackagers and relabelers. The FDA regulates Lamivudine, Zidovudine Drug Combination manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lamivudine, Zidovudine Drug Combination API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Lamivudine, Zidovudine Drug Combination supplier is an individual or a company that provides Lamivudine, Zidovudine Drug Combination active pharmaceutical ingredient (API) or Lamivudine, Zidovudine Drug Combination finished formulations upon request. The Lamivudine, Zidovudine Drug Combination suppliers may include Lamivudine, Zidovudine Drug Combination API manufacturers, exporters, distributors and traders.
Lamivudine, Zidovudine Drug Combination Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lamivudine, Zidovudine Drug Combination GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lamivudine, Zidovudine Drug Combination GMP manufacturer or Lamivudine, Zidovudine Drug Combination GMP API supplier for your needs.
A Lamivudine, Zidovudine Drug Combination CoA (Certificate of Analysis) is a formal document that attests to Lamivudine, Zidovudine Drug Combination's compliance with Lamivudine, Zidovudine Drug Combination specifications and serves as a tool for batch-level quality control.
Lamivudine, Zidovudine Drug Combination CoA mostly includes findings from lab analyses of a specific batch. For each Lamivudine, Zidovudine Drug Combination CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lamivudine, Zidovudine Drug Combination may be tested according to a variety of international standards, such as European Pharmacopoeia (Lamivudine, Zidovudine Drug Combination EP), Lamivudine, Zidovudine Drug Combination JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lamivudine, Zidovudine Drug Combination USP).
LOOKING FOR A SUPPLIER?
